Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies Signs Collaboration Agreement with Ostiones Guerrero SA de CV to Expand KLH Aquaculture Operations
Jul 28 15
Stellar Biotechnologies, Inc. announced that the company has entered into a collaboration agreement with Ostiones Guerrero SA de CV to secure a unique strategic site in Baja California, Mexico for the development of an additional aquaculture locale and expansion of Stellar KLHTM production to meet the increasing needs of its customers. Stellar provides clinical-stage biotechnology companies with KLH, an immune-stimulating protein that is an essential ingredient in a number of human immunotherapies in various stages of clinical development. KLH can only be obtained from a scarce marine mollusk, the Giant Keyhole Limpet, which is native to a limited stretch of Pacific Ocean coastline. Under the terms of the Agreement, Stellar and Ostiones will collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities in Baja California, Mexico to provide, exclusively for Stellar, an additional site for hatchery and maturation of keyhole limpets and production of KLH. The venture will provide Ostiones with access to advanced aquaculture techniques, proprietary expertise, support services and training that will form the basis for expanding its seafood production business. Additionally, the companies are joining forces to share their vision of protecting the natural
resources of the Pacific Ocean. Stellar has developed a proprietary process for KLH harvesting that does not harm the Giant Keyhole Limpets. Similarly, Ostiones is committed to sustaining
ocean wildlife populations. The companies are committed to marine ecosystem sustainability as a commercial priority.
Stellar Biotechnologies, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 02:00 PM
May 29 15
Stellar Biotechnologies, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 02:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.
Stellar Biotechnologies, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015
May 11 15
Stellar Biotechnologies, Inc. reported consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported total revenues of $187,627 compared to $114,371 for the same period a year ago. Net loss was $426,164 or $0.01 per basic and diluted share compared to $1,433,854 or $0.02 per basic and diluted share for the same period a year ago.
For the year, the company reported total revenues of $400,288 compared to $173,196 for the same period a year ago. Net loss was $1,769,641 or $0.02 per basic and diluted share compared to $7,011,044 or $0.09 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,581,458 compared to $2,560,177 for the same period a year ago. The decrease in net loss reported in the quarter and six months ended March 31, 2015 compared to the same periods in 2014 was primarily due to significant noncash gains in the fair value of warrant liability, increased revenues and decreased research and development expenses, net of increased general and administrative expenses and increased noncash foreign exchange loss.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|